Trial Profile
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs GSK 2256098 (Primary) ; Abemaciclib; Capivasertib; Vismodegib
- Indications Meningioma
- Focus Therapeutic Use
- 26 Oct 2022 Results evaluating the efficacy of GSK2256098 in recurrent or progressive grade 1-3 meningiomas ,published in the Journal of Clinical Oncology
- 15 Sep 2021 Planned number of patients changed from 69 to 124.
- 15 Sep 2021 Status changed from suspended to recruiting.